BBOT vs OGN · $610.4M cap vs P/E 3.4, rev $6.40B
BridgeBio Oncology Therapeutics, Inc. (BBOT) versus Organon & Co (OGN) — a side-by-side from cached financials, not a winner call.
BridgeBio Oncology Therapeutics, Inc. (BBOT) is a biotechnology company listed on NASDAQ.
Organon & Co (OGN) is a drug manufacturers - general company listed on US.
BBOT does not have a complete income-statement cache yet.
Latest reported OGN revenue for 2024-12-31 was $6.40B. Net income was $864.0M. Revenue was up 2.2% from 2023-12-31 to 2024-12-31. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
BBOT currently screens at market cap $610.4M. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
Not investment advice. Open the BBOT and OGN stock pages for the full models.
Not investment advice.